Seres Therapeutics (MCRB) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Seres Therapeutics (NASDAQ:MCRB) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.03, Fidelity Earnings reports. The company had revenue of $9.06 million during the quarter, compared to analysts’ expectations of $23.43 million. Seres Therapeutics had a negative net margin of 264.31% and a negative return on equity of 256.24%.
MCRB stock traded down $0.48 during midday trading on Friday, reaching $8.40. The company had a trading volume of 155,488 shares, compared to its average volume of 100,299. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.76 and a quick ratio of 2.76. Seres Therapeutics has a 1 year low of $5.64 and a 1 year high of $11.35. The stock has a market cap of $330.04 million, a PE ratio of -3.80 and a beta of 0.61.
In other Seres Therapeutics news, insider John G. Aunins sold 14,279 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $5.94, for a total value of $84,817.26. Following the completion of the transaction, the insider now owns 103,811 shares of the company’s stock, valued at approximately $616,637.34. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Roger Pomerantz sold 12,518 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $9.10, for a total transaction of $113,913.80. Following the completion of the transaction, the insider now directly owns 218,799 shares of the company’s stock, valued at approximately $1,991,070.90. The disclosure for this sale can be found here. In the last three months, insiders sold 69,634 shares of company stock valued at $526,006. Corporate insiders own 37.10% of the company’s stock.
Several brokerages recently commented on MCRB. Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 1st. Oppenheimer set a $16.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Friday. BidaskClub raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Chardan Capital began coverage on shares of Seres Therapeutics in a research note on Monday, October 22nd. They set a “buy” rating and a $15.00 price objective for the company. Finally, ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Seres Therapeutics has a consensus rating of “Hold” and a consensus price target of $13.81.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/11/10/seres-therapeutics-mcrb-announces-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Featured Story: How a Put Option Works
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.